223785-66-8

Usage

Uses

Used in Pharmaceutical Research:
(S)-Benzyl 2-(2-bromoacetyl)pyrrolidine-1-carboxylate is used as a building block in the synthesis of various pharmaceutical compounds, contributing to the development of new drug molecules due to its unique structure.
Used in Drug Synthesis:
In the field of drug synthesis, (S)-benzyl 2-(2-bromoacetyl)pyrrolidine-1-carboxylate is utilized for its potential to create novel drug molecules, taking advantage of its structural properties and the biological activity suggested by the pyrrolidine moiety.
Used in Medicinal Chemistry:
(S)-Benzyl 2-(2-bromoacetyl)pyrrolidine-1-carboxylate is employed as a target for further investigation in medicinal chemistry, with the aim of uncovering its potential biological activities and applications in the development of therapeutic agents.

Upstream product

• 56633-71-7 2-(S)-(2-diazo-1-oxoethyl)pyrrolidine-1-carboxylic acid benzyl ester 
• 105414-01-5 Cbz-L-Pro-OCO₂-i-Bu 
• 5211-23-4 N-carbobenzyloxy-L-proline methyl ester 
• 501-53-1 benzyl chloroformate 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1035279-41-4 (S)-benzyl-2-(8-bromoimidazo[1,2-a]pyridin-2-yl)pyrrolidine-1-carboxylate 
• 1035279-32-3 C₁₉H₁₈BrN₃O₂ 
• 1246471-52-2 C₂₁H₂₀BrN₃O₂ 
• 623938-26-1 (2S)-(-)-phenylmethyl 2-(1,2-dihydroxyethyl)pyrrolidine-1-carboxylate 
• 1035279-36-7 C₁₇H₁₇N₃ 
• 1035278-87-5 (S)-benzyl 2-(8-phenylimidazo[1,2-a]pyridin-2-yl)pyrrolidine-1-carboxylate 
• 1035279-34-5 C₂₅H₂₃N₃O₂ 
• 1035278-84-2 C₂₈H₃₅N₅O₃ 
• 1035279-38-9 C₃₃H₄₃N₅O₅ 
• 1257239-44-3 C₂₁H₃₀BrN₃O₃Si 

Relevant academic research and scientific papers

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

BIARYL INHIBITORS OF THE SODIUM CHANNEL

The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns biaryl derivatives (e.g., compounds according to any of Formulas (I)-(XII) or Compounds (l)-(372) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES

Fused tricyclic compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein X1, X2, X3, X4, Y1, Y2, M1, M2, Ra, Rb, R1, R2 and R6 are as defined in the description. Compositions comprising at least one fused tricyclic compound and methods of using the fused tricyclic compounds for treating or preventing HCV infection in a patient are also disclosed.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C

The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56